Lowering Costs for Weight Loss Drugs
Eli Lilly has begun selling higher doses of its weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, aiming to spur demand for the medicine and increase availability. The company's new offer includes 7.5 milligram and 10mg vials priced at $499 per month on its website, nearly 23% less than what patients are charged for auto-injectors. This move comes as Lilly seeks to improve sales, which have been weighed down by concerns over signs of weakness in sales.
- The reduced pricing may lead to increased adoption of Zepbound among patients, potentially benefiting from the improved affordability and access offered by Eli Lilly's new vial packaging.
- Will this shift towards more affordable versions of weight loss medications influence other pharmaceutical companies to adopt similar strategies, and how will this impact the broader market for these treatments?